Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <scp>PARAGON‐HF</scp>

202230 citationsJournal Articlehybrid Open Access

Authors

Alexander Peikert · Harvard University

Muthiah Vaduganathan · Harvard University

Finnian R. Mc Causland · Harvard University

Brian Claggett · Brigham and Women's Hospital

Safia Chatur · Brigham and Women's Hospital

Milton Packer · Baylor University Medical Center

Marc A. Pfeffer

Abstract

Sacubitril/valsartan, compared with valsartan, attenuates the decline of eGFR and reduces clinically relevant kidney events similarly among patients with HFpEF with and without diabetes.

Topics & Keywords

Heart Failure Treatment and Management Diabetes Treatment and Management Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

Volume 24, Issue 5, pp. 794-803

DOI: 10.1002/ejhf.2450

Field-Weighted Citation Impact: 4.73